Enterococci constitute a minor component of the healthy human microbiota (1). Enterococci, 54 including Enterococcus faecalis, are also nosocomial pathogens that cause a variety of diseases, 55 including sepsis, endocarditis, surgical-site, urinary tract and mixed bacterial infections (2, 3). 56Over recent decades, enterococci have acquired extensive antibiotic resistance traits, including 57 resistance to "last-resort" antibiotics such as vancomycin, daptomycin, and linezolid (4-8). 58Following antibiotic therapy, multi-drug resistant (MDR) enterococci can outgrow to become a 59 dominant member of the intestinal microbiota, resulting in intestinal barrier invasion and blood 60 stream infection (7, 9). The ongoing evolution of MDR enterococci in healthcare settings (4-6, 10, 61 11) and their ability to transmit antibiotic resistance among diverse bacteria (9, 12-15), emphasize 62 the immediate need for novel therapeutic approaches to control enterococcal infections. 63Viruses that infect and kill bacteria (bacteriophages or phages) are receiving attention for their 64 use as antibacterial agents (16). Recent studies have demonstrated the efficacy of anti-65 enterococcal phages in murine models of bacteremia (17)(18)(19) and the administration of phages to 66 reduce E. faecalis burden in the intestine gives rise to phage resistant isolates that are 67 resensitized to antibiotics (20). Considering phages are highly specific for their target bacterium, 68 coupled with the self-limiting nature of their host-dependent replication, suggests that unlike 69 antibiotics which have broad off-target antimicrobial activity, phages are likely to have nominal 70 impact on bacteria outside of their intended target strain (21-23). However, our understanding of 71 how phages interact with bacteria and the bacterial response to phage infection is limited. 72While studying the transcriptional response of phage infected E. faecalis cells, we discovered 73 that phage infection induced the expression of genes involved in the biosynthesis of a type VIIb 74 secretion system (T7SS) (24). Firmicutes, including the enterococci, harbor diverse T7SS genes 75 encoding transmembrane and cytoplasmic proteins involved in the secretion of protein substrates 76 (25), and T7SSs promote antagonism of non-kin bacterial cells through contact-dependent 77 secretion of antibacterial effectors and/or toxins (26, 27). The antibacterial activity of T7SSs from 78 96 Results 97
Phage mediated induction of E. faecalis T7SS leads to interspecies antagonism. 98A hallmark feature of phage therapy is that because phages often have a narrow host range, 99 they will not influence the growth of non-susceptible bacteria occupying the same niche (22). We 100 discovered that infection of E. faecalis OG1RF by phage VPE25, induces the expression of T7SS 101 genes (24). The E. faecalis OG1RF T7SS locus is absent in the commonly studied vancomycin-102 resistant strain V583, despite conservation of flanking genes (Fig. 1A) (32, 33). Homologs of the 103 E. faecalis T7SS ...